Jazz Pharmaceuticals

News

Trial of Jazz' cannabis drug in glioblastoma will start next...

An investigator-led trial of Jazz Pharma's cannabis extract-based drug Sativex in glioblastoma – an aggressive form of brain cancer - will get underway in the UK next year.

News

Jazz lifted by third EU approval for GW Pharma's Epidyolex

GW Pharmaceuticals' Epidyolex has been approved in the EU for a third epilepsy indication, giving a boost for the company ahead of its $7.2 billion

News

Jazz agrees $7.2bn deal to buy cannabis meds pathfinder GW P...

Jazz Pharma has agreed a $7.2 billion deal to by GW Pharmaceuticals and its pioneering cannabis-derived medicines, headed by childhood epilepsy drug Epidiolex.

News

Harmony's sleep disorder drug Wakix gets US label extension

Harmony Biosciences has scored an expanded use for its Wakix narcolepsy drug to include cataplexy – a symptom of the sleep disorder that can cause total body collapse.

News

FDA approves Jazz Pharmaceuticals' narcolepsy therapy

The FDA has approved Jazz Pharmaceuticals’ sleep disorder drug Xywav, to treat daytime sleepiness in patients with narcolepsy, offering a regime with less sodium than standard therapy.

News

Jazz targets US launch of SCLC drug after FDA grants fast re...

PharmaMar and Jazz Pharmaceuticals have announced the FDA has granted a six-month Priority Review for their lurbinectedin for relapsed small cell lung cancer (SCLC).

Trial of Jazz' cannabis drug in glioblastoma will start next...

Jazz lifted by third EU approval for GW Pharma's Epidyolex

Jazz agrees $7.2bn deal to buy cannabis meds pathfinder GW P...

Harmony's sleep disorder drug Wakix gets US label extension

FDA approves Jazz Pharmaceuticals' narcolepsy therapy

Jazz targets US launch of SCLC drug after FDA grants fast re...

Recordati gets €10.9bn takeover bid from private equity firm

Using AI-driven synthetic personas to take your insights fur...

Jazz Pharmaceuticals

Editor's Picks